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Abstract
Background: Notch signaling pathway controls key functions in vascular and endothelial cells (ECs) where Notch4 plays a
major role. However, little is known about the contribution of other Notch receptors. This study investigated regulation of
Notch2 and further examined its implication in EC dysfunction.
Methodology/Principal Findings: Here, we provide evidence for a novel link between Notch and TNF signaling, where
Notch2 is upregulated and activated in response to TNF. Forced expression of Notch2 intracellular domain in cultured ECs
promotes apoptosis and allows the significant downregulation of several cell-death-related transcripts in a dose-dependent
manner. In particular, activation of Notch2 led to a rapid decrease in survivin mRNA and protein expression, while survivin
upregulation was obtained by the selective knockdown of Notch2 in ECs, indicating that survivin expression is controlled at
the Notch level. Moreover, Notch2 silencing and ectopic expression of survivin, but not XIAP or Bcl2, rescued ECs from TNF
and Notch2-mediated apoptosis, respectively.
Conclusions/Significance: In conclusion, TNF signaling activates Notch2 that sensitizes ECs to apoptosis via modulation of
the key apoptosis regulator survivin. Overall, our findings also indicate that specific Notch receptors control distinct
functions in vascular cells and inflammatory cytokines contribute to this specificity.
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Introduction
Notch signaling pathway regulates a broad array of cell fate
decisions in various tissues and in all stages of development
(embryonic to adult). The Notch family comprises heterodimer
transmembrane receptors consisting of an extracellular domain
and a noncovalently linked intracellular domain (ICD). In
mammals, 4 Notch receptors (Notch1-4) and 5 ligands (Delta-
like [Dll]-1, Dll3, Dll4, Jagged1 and Jagged2) have been identified
[1]. Upon interaction with ligands on neighbouring cells, Notch
undergoes proteolytic cleavages managed sequentially by ADAM
proteins (a desintegrin and metalloproteinase) and the c-secretase
complex. Release of the cytoplasmic Notch C-terminal intracel-
lular domain (NICD) from the plasma membrane is followed by its
translocation into the nucleus where it forms a complex with CSL,
removing the repression and allowing for target genes (hes, hey)
transcription [2].
Notch proteins display a selective cellular and tissue distribution.
The vascular cells express all four Notch receptors but only
Notch4 displays an almost exclusively endothelial expression
pattern whereas Notch1-3 are expressed more ubiquitously [3]. In
the vasculature, Notch1 and Notch4 are predominantly endothe-
lial, prominent in both arteries and veins while the expression of
Notch2 has been reported in pulmonary endothelium [4]. Notch3
is primarily expressed in adult arterial vascular smooth muscle cells
(VSMCs). In addition to a specific pattern of tissue expression,
several observations suggest that temporal regulation of Notch
signaling may be equally important to control the diverse functions
of the Notch family. Notch signaling plays a critical role in
vascular development and homeostasis [5] and is involved in
vasculogenesis, angiogenesis, differentiation, vascular remodeling,
and maturation [6]. Combined deletion of Notch1 and Notch4 genes
enhances the defects in vasculature remodeling observed in
Notch1 single knock-out mice [7]. Endothelial cell (EC)-specific
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lethality with abnormal vessel structure and patterning [8].
Constitutive activation of Notch4 in ECs also causes defects in
vascular remodeling [8]. In vitro experiments also demonstrate that
Notch4 activation protects ECs from apoptosis, promotes
endothelial-to-mesenchymal trans-differentiation and blocks both
proliferation and angiogenesis [9,10].
Endothelial cells control vascular tone, leukocyte adhesion and
thrombosis by fine-tuned regulation of many cell surface and
soluble molecules [11]. EC activation is considered to be an early
event which subsequently leads to EC dysfunction and ultimately
to vascular injury, key events associated with acute and chronic
inflammation, such as occurs during sepsis, atherosclerosis and
acute vascular and chronic allograft rejection. Tumor necrosis
factor (TNF), an important mediator of innate inflammation, acts
on vascular ECs to promote the inflammatory response. In
cultured human ECs, human TNF causes apoptosis, especially in
the presence of RNA or protein synthesis inhibitors such as
actinomycin D or cycloheximide (CHX), respectively. TNF
activates both NFkB and AP-1 in ECs, leading to the expression
of pro-inflammatory proteins, such as E-selectin (CD62E), ICAM-
1 (CD54), VCAM-1 (CD106) and IL-8. TNF also promotes
expression of an array of ‘‘protective’’ genes including the zinc
finger protein A20, heme-oxygenase-1 (HO-1) and Bcl-xL [12]. It
has been suggested that Notch is necessary for the establishment
and/or maintenance of quiescent EC phenotype [10]. However, a
role for Notch signaling in activated EC phenotype and function
upon inflammation has not been documented.
In a previous study, we showed that impaired Notch4
expression caused by pro-inflammatory cytokines in cardiac
allograft vessels promotes EC dysfunction and transplant arterio-
sclerosis [13]. Although the importance of Notch4 in controlling
EC proliferation, differentiation and survival has been established,
little is known about the role of Notch2 expressed on vascular
endothelium. This study further investigates the regulatory
crosstalk between TNF signaling and Notch receptors expression
and activity in primary cultures of human vascular ECs. In
particular, we show that TNF strongly upregulates Notch2 on
vascular ECs. Moreover, the present work establishes the direct
contribution of Notch2 signaling in the transcriptional regulation
of several pro- and anti-apoptotic molecules. Both forced Notch2
NICD (N2ICD) expression and Notch2 silencing demonstrate
interplay between Notch2 signaling and survivin expression in the
control of EC apoptosis. Taken together, our findings indicate that
dysregulated Notch2 signaling by TNF sensitizes vascular
endothelial cells to apoptosis by the downregulation of a set of
mediators of apoptosis and suggest a major role for survivin as
effector of Notch signaling.
Materials and Methods
Ethics Statement
Informed written consent was obtained from patients. The study
was performed according to the guidelines of the local ethics
committee (Comite ´ Consultatif de Protection des Personnes dans
la Recherche Biome ´dicale [CCPRB], CHU de Nantes, France).
Cell Culture and Reagents
Primary ECs cultures from human artery (HAEC) and umbilical
vein (HUVEC) were isolated and grown in early passages (2–6) as
we previously reported[14]. Human aortic endothelial cells
(HAECs) were isolated from unused aortic pieces collected at the
time of kidney transplantation and harvested according to good
medical practice and stored in the DIVAT Biocollection (French
Health Minister Project no. 02G55). HUVEC were only used for
plasmid transfection experiments. ECs were cultured in endothe-
lial basal growth medium (ECBM, Promocell, Heidelberg,
Germany) supplemented with 10% fetal calf serum (FCS), 0.4%
EC growth supplement/heparin, human epidermal growth factor
(0.1 ng/mL), human basic fibroblast growth factor (1 ng/mL),
hydrocortisone (1 mg/mL), gentamicin (50 mg/mL), and ampho-
tericin (50 ng/mL). Before activation, confluent EC monolayers
were maintained for 24 h in basal ECBM supplemented with 2%
FCS and then incubated with Human Recombinant TNF
(100 U/mL, provided by Professor P. Neuman, BASF, Ludwig-
shafen, Germany). To induce EC apoptosis, ECs were pre-treated
1 h with 100 mM pyrrolidine dithiocarbamate (PDTC, Sigma–
Aldrich, St. Louis, MO, USA) before TNF addition and
incubation for 24 h. To protect ECs from apoptosis, AdN2ICD-
transduced cells were cultured for 48 h in presence of zvad (R&D
systems).
DNA Constructs, Small Interfering RNAs and
Transfections
The luciferase reporter plasmid that contains 4 copies of a
binding site for CBF1 (CBF1-Luc) was a kind gift from Dr. Diane
Hayward (Johns Hopkins University, Baltimore, Maryland,
USA)[15]. Cells were treated with DAPT (10 mM, N-[N-(3,5-
Difluorophenacetyl)-L-alanyl]-Sphenylglycine t-butyl ester, Sig-
ma–Aldrich) or co-transfected with the N2IC/MSCV plasmid
encoding Notch2 NICD as a positive control for Notch
activity[16]. Gene reporter activity was measured with the
luciferase assay (Promega, Madison, WI, USA) and expressed as
a relative luciferase activity after normalization to protein content.
HUVEC were transfected at 70–90% confluence using the
Lipofectamine and the PLUS reagent (Invitrogen, Carlsbad, CA,
USA) for 1 h at 37uC in DMEM. Survivin, Bcl2 and XIAP full
cDNAs were cloned into pcDNA3.1 vector. For gene silencing,
10
5 HAECs were transfected in 6-well plates with RNAiMax
lipofectamineH (Invitrogen) and siRNA targeting Notch2
(ID#144339, 72% knockdown, ID#144349, 78% knockdown,
ID#144373) or a scrambled negative control (#AM4611) at a
final concentration of 10 nM (Ambion, Austin, TX, USA). High
transfection efficiency was verified with fluorescent siRNA (over
85%) (fluorescent Block-ITH, invitrogen). Validation of siRNA and
functional assays were performed 48 h post-transfection. For each
experiment, specific expression knockdown (.70%) was estab-
lished by qRT-PCR.
Generation of a Recombinant Adenoviral Vector
Encoding Notch2ICD
The N2IC/MSCV plasmid encoding Notch2 NICD was
kindly provided by Dr Christopher A. Klug CA (University of
Alabama at Birmingham, AL, USA). The 2.3-kbp EcoRI
fragment from N2IC/MSCV, containing the coding region of
Notch2 intracellular domain was subcloned into pT/BH vector.
The EcoRV-NotI fragment was then inserted under the
cytomegalovirus promoter into the vector pTrackCMV that
contains a second expression cassette for GFP dependant on
CMV promoter. The resultant pTrackCMV-N2ICD vector was
tested in HUVEC transfections before adenovirus generation.
The recombinant adenovirus AdN2ICD was produced in the
human embryonic kidney 293 cells by the vector core laboratory
of the University Hospital of Nantes (INSERM UMR 649 Gene
Therapy Laboratory, Nantes, France) as we previously de-
scribed[17]. The recombinant adenoviruses AdTrack-GFP and
–AdNull (Ad Dl324) without GFP cDNA were used as a control
Notch2 in Endothelial Survival
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expression are shown in the supplemental Figure S1. When
applicable, dose-reponse of multiplicity of infection (moi) were
performed to confirm/validate our findings. HAEC or HUVEC
were cultured 70–90% confluence and infected with a moi of 30/
cell or 300 for AdN2ICD and AdNull and 5 moi or 50 for
AdGFP, respectively. Adenoviral infection was carried out in
ECGM supplemented with 1% FCS for 3 h at 37uC, 5% CO2
under agitation. The cells were washed with medium containing
10% FCS and grown in fresh supplemented endothelial cell
growth medium. Transduction efficiency was analyzed 24 h after
infection through GFP detection by direct microscopy imaging
and Flow Cytometry using a FACScaliburH (BD Biosciences,
Franklin Lakes, NJ, USA).
Reverse Transcription-Polymerase Chain Reaction RT-PCR
& PCR Arrays
RNA was isolated using Trizol reagent (Invitrogen) and treated
with Turbo DNaseH (Ambion) before reverse transcription (RT).
Subsequent to RT, cDNAs were amplified by PCR and analyzed in
agarose gels stained with ethidium bromide. Quantitative PCRs were
performed using the ABI PRISM 7700 and 7900 sequence detection
application program (PE Applied Biosystems,Foster City, CA, USA).
For quantification, duplicates were normalized by the concomitant
quantification of hypoxanthine-guanine phosphoribosyl transferase
(HPRT). Relative expression was calculated according to the 2
2DDCt
method, as previously described[18]. Primers for Notch1 (59-
GACGGACCCAACACTTACAC-39;59-TCAGGCAGAAGCAG-
AGGTAG-39), Notch2 (59-GCAGGAGGTGGATGTGTTAG-39;
59-CCAGGATCAGGGGTGTAGAG-39), Notch3 (59-CTCAT-
CCGAAACCGCTCTAC-39;59-AGTCTCTCCTGGGCTACGT-
C-39), Notch4 (59-TGTTTGATGGCTACGACTGT-39;59-TC-
CTTACCCAGAGTCCTACC-39), hey1 (59-CAGGCAACAGG-
GGGTAAAGG-39;59-GTGGAGCGGATGATGGTGGT-39)a n d
b-actin (59-TCTGGCACCACACCTTCTAC-39;59 CAGCTTCT-
CCTTAATGTCAC-39) were obtained from MWG (High Point,
NC, USA) and used for RT-PCR analysis. Human Apoptosis PCR
array primer sets (Real Time Primers, Elkins Park, PA, USA) were
used at a 0.3 mM final concentration. Transcript levels were
quantified by qRT-PCR with the following primers and probe from
Applied Biosytems: Notch2 (Hs00225747_m1), hey1 (Hs00232618_
m1), survivin (Hs00977611_g1), bim (Hs00197982_m1), DAPK2
(Hs00204888_m1), HRK (Hs00705213_s1), DR5 (Hs00366272
>_m1), CD40 (Hs00374176_m1), APRIL (Hs00182565_m1) and
HPRT (H99999909_m1).
Western Blot Analysis
Cells were lysed on ice in RIPA lysis buffer supplemented with
Protease Inhibitors Cocktail (PIC, Sigma–Aldrich). Cell lysates
were resolved by SDS-PAGE (7.5%–10%) and subjected to
Western immunoblot using specific antibodies for Notch2 (DSHB,
Iowa City, IA, USA), cleaved-Notch2 (Millipore, Temecula, CA,
USA) survivin (R&D Systems, Abingdon, UK), VCAM-1 (Santa
Cruz Biotechnology), and GAPDH (Oncogene, MERCK Euro-
Lab, Val de Fontenay, France) and secondary horseradish
peroxidase-labeled antibodies (CST, St Quentin-en-Yveline,
France; Serotec, Martinsried, Germany). Antibody-bound proteins
were detected using an enhanced chemiluminescence kit (ECL,
Amersham, Buckinghamshire, UK). Results shown are represen-
tative of at least 3 independent experiments.
For Immunofluorescence, cytospins of ECs transfected with
pTrackCMV-N2ICD were subjected to Notch2 labelling with
Notch2 antibody (DSHB).
Cell Viability and Apoptosis Analysis
DNA content. Cellular DNA content analyses were
performed by flow cytometry as follows: 48 h after transfection,
ECs were harvested using trypsin/EDTA, washed twice in PBS,
fixed in ice-cold 70% ethanol under vortexing, and incubated for
24 h at 4uC. Fixed cells were then stained with 50 mg/mL
propidium iodide (PI), 100 mg/mL RNase A (Sigma-Aldrich) in
PBS (1 ml/1610
6 cells). For specific apoptosis detection, ECs were
harvested, washed and resuspended in 100 ml of Binding Buffer
(10 mM HEPES, pH 7.4, 140 mM NaCl, 2.5 mM CaCl2) with
5 ml of annexin V-APC (BD Biosciences, Franklin Lakes, NJ, USA)
for 15 min and with 50 ml/mL of PI for 5 min. Fluorescence was
measured on 10,000 cells/sample using a LSR IIH (BD
Biosciences) and analyzed using FlowJoH software (Tree Star,
Inc.). Results shown are representative of at least 3 independent
experiments.
Measurement of caspase activity. Caspases-3 and -7
activity was assessed using the Caspase-GloH 3/7 Assay,
according to the manufacturer’s recommendation (Promega,
Charbonnieres, France). Briefly, 10 mg of cell lysate were
incubated with caspase substrate and fluorescence was analyzed
for 2 h with a Fluoroskan Ascent
TM(Thermo Scientific, Saint-
Herblain, France).
Caspase activity was also analyzed by western blot using
antibodies against Cleaved Caspase-3 (Asp175), Cleaved Caspase-
6 (Asp162), Cleaved Caspase-7 (Asp198), Cleaved Caspase-9
(Asp315), Cleaved Caspase-9 (Asp330) and Cleaved PARP
(Asp214) from CST and antibody against total caspase-3 (Santa
Cruz Biotechnology, CA, USA).
The cell-permeable fluorigenic peptidic substrate PhiPhiLux-
G2D2 (OncoImmunin, Gaithersburg, MD) containing the cleav-
age site DEVD was used to monitor caspase-3-like activity in intact
cells. Cells were incubated with the substrate solution for 1 h at
37uC in the dark, according to the manufacturer’s instructions.
Caspase 3 activation/apoptosis was followed during 18 h by time
lapse imaging using a microscope DMI6000B (Leica Microsys-
te `mes SAS. Rueil Malmaison) equipped with an objective lens
X40 (HCX FL Plan), and a CCD camera (Coolsnap HQ2,
Photometrics Roper Scientifics SAS Evry). Caspase 3 positive
cells/fied were counted every 2 h between 48 h and 66 h post-
infection with AdN2ICD and controls adenovirus. Results were
expressed as the percentage of caspase-postive ECs.
Cell Proliferation
Cells were seeded at 25% of confluence, treated with FGF-2
(R&D Systems) and pulsed for 16 h with 0.5 mCi/well
[methyl-
3H] thymidine (Amersham, Les Ulis, France). Thymidine
incorporation was measured using a scintillant counter (Top count
NXT, Perkin Elmer, Waltham, Massachussetts, MA, USA).
Statistics
Data are represented as means6SEM for replicates experi-
ments. Statistical analysis was performed with Graphpad PrismH
Software (Graphpad Software, San Diego, CA) by the parametric
analysis of variance test as appropriate. p,0.05 was considered
statistically significant.
Results
TNF Induces Notch2 Signaling in Vascular ECs
TNF in human vascular ECs activates signaling pathways that
regulate coordinately the transcription of a large set of molecules
involved in inflammation, coagulation, thrombosis, vascular tone,
immune response [11]. Moreover, TNF signaling also regulates a
Notch2 in Endothelial Survival
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EC survival and, ultimately, vascular injury and remodeling [19].
Consequently, the first aim of this study was to investigate how
TNF signaling may control the expression of Notch receptors
(Notch1, 2, 3 and 4) in cytokine-activated ECs. Firstly, primary
cultures of ECs were treated for 0 to 24 h with recombinant TNF
and transcript levels were analyzed by RT-PCR. As shown in
Figure 1A, TNF selectively modulates the mRNA steady-state
levels of the Notch receptors. TNF decreases transcript levels for
Notch1, Notch3 and Notch4 with a significant effect starting 2 h
after treatment and with a maximal inhibition at 24 h of 4967%,
8862% and 7862% for Notch1, 3 and 4 as compared with basal
levels (p,0.05 for all). In contrast, an enhanced mRNA level for
Notch2 was found in response to TNF, corresponding to a
3.360.3-fold increase at 24 h (p,0.05) as compared with the basal
mRNA level. TNF-regulated expression for Notch2 was further
confirmed by western blotting (Figure 1B–D). TNF also triggers
the activation of Notch2 signaling as reflected by the induction of
the activated cleaved-form of Notch2 receptor (c-Notch2)
(Figure 1B). Expression of, Hairy/Enhancer of split (hes) and
Hairy-related (hey) transcription factors has been shown to be
dependent on Notch receptors activation [2]. Among these
molecular targets of Notch activity, TNF was found to drive a
selective increase in hey1 mRNA (Figure 1E) while, in contrary,
hes1 and hey2 mRNA exhibit a significant decrease (data not
shown). Activation of Notch signaling in response to TNF,
reflected by hey1 transcription, measure by qRT-PCR, was
strongly abrogated in the presence of a c-secretase inhibitor
(DAPT) (Figure 1F). Together, these findings indicate that TNF
strongly modulates the pattern of Notch receptors expressed in
ECs by increasing Notch2 expression and activity in parallel to the
induction of hey1 effector gene.
Notch2 Signaling Elicits EC Death and Apoptosis
Despite the strong implication of Notch in endothelial and
vascular biology, there have been few studies addressing the role of
Notch2 in vascular cell phenotype and function. Our analysis thus
focused on regulating the Notch2 pathway in human vascular
ECs. To this end, we first generated a recombinant adenoviral
vector encoding the intra-cellular domain of Notch2 (N2ICD) and
GFP as a reporter gene (AdN2ICD). Controls were ECs
transduced with a recombinant adenovirus encoding GFP alone
and empty vector (AdGFP and AdNull) to account for any effects
that may be due to adenoviral infection or/and GFP expression.
Figure 1. Regulation of Notch2 signaling in response to TNF. (A) RT-PCR for Notch1-4 in ECs treated with TNF. A western blotting analysis (B)
and its quantification showing the expression of the native Notch2 (C) and the activated cleaved form (cNotch2) in response to TNF (D). (E) RT-PCR
for Notch2 and hey1 in ECs treated with TNF. (F) qRT-PCR for hey1 in EC stimulated with TNF and DAPT. *p,0.05 versus controls.
doi:10.1371/journal.pone.0008244.g001
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dose-dependent in transduced ECs (supplemental Figure S1C).
Validation of the N2ICD transgene was also attested by its nuclear
translocation as well as its ability to promote canonical Notch
pathway activity (supplemental Figure S1D-E).
Notch2 signaling was then tested for regulation of EC survival.
First, the effect of N2ICD on EC viability was examined by a
DNA content analysis from 24 h to 72 h after infection (Figure 2A).
At 24 h, no significant effect was observed. At 48 h, a significant
decrease in cell viability (46.565.9%) was found when ECs were
infected with AdN2ICD at moi 40 while a lower dose of virus (moi
20) decreases cell survival by 31.868.4% indicating that N2ICD-
induced cell death is a dose-dependent process. Finally, at 72 h
post-infection, in contrast to AdGFP and AdNull controls that did
not alter cell survival, AdN2ICD was sufficient to drastically
induce cell death (40.0614.0% and 67.566.1% of cell death for
moi 20 and 40, respectively). To test whether EC death reflected
apoptosis, ECs were labeled with AnnexinV and Propidium iodide
72 h after infection and apoptotic cells (AnnV+) were detected by
flow cytometry. As shown in Figure 2B, N2ICD strongly induces
apoptosis in a dose dependent manner. AdN2ICD transduced ECs
displayed 58.2% and 77.5% of apoptotic cells for moi 20 and 40,
respectively. In contrary, no effect was observed after AdGFP
infection or with the corresponding empty Adenovirus at a moi of
40 thus attesting that the deleterious effect of AdN2ICD was not
due to GFP nor to the viral charge. No necrotic cells (AnnV-PI+)
were detected. To further characterize N2ICD-mediated apopto-
sis, we first used a PhiPhiLux
TM system to detect real-time
activation of caspase in live cells. PhiPhiLux incorporated into a
cell is specifically cleaved by caspase-3 or caspase-7, and the
cleaved products give fluorescence that can be detected by
fluorescent Time lapse videomicroscopy imaging. After 48 h
post-infection, ECs were subjected to time lapse imaging for 18 h
(Figure 2C). Caspase3/7 positive cells/field (in %) were counted
every 2 hours during the experiment (Figure 2D). This experi-
mental setting allowed us to follow AdN2ICD-mediated apoptosis
induction in reat time. As shown for AnnexinV staining,
AdN2ICD was associated with a high number of caspase3/7-
dependent apoptosis (37%) as compared to AdGFP and AdNull
controls (5% and 2%, respectively) 66 h after infection.
Moreover, western blots were used to examine cleavage of
caspase-3, -6, 7-9 and PARP in response to Notch2 NICD
(Figure 2E). The 17-kDa form of cleaved caspase-3 was detected in
EC overexpressing N2ICD at 48 and 72 h and parallels a decrease
in full caspase-3 expression. Correlated to caspase-3 activation,
clivage of caspase-7 and PARP were also observed. In contrast, no
cleavage of caspase-6 and -9 was found (data not shown). To
quantify caspase activation by N2ICD, we used a colorimetric
assay for caspase-3 and -7 activation. As shown in Figure 2F, ECs
overexpressing N2ICD exhibited a strong caspase activity as
compared to AdGFP and AdNull controls (40.9 fold and 93.4 fold
increase, respectively).
Protective effect of the pan caspase inhibitor Z-VAD-FMK in
AdN2ICD-transduced ECs further confirmed that Notch2 medi-
ates EC death by inducing caspase-mediated apoptosis (supple-
mental Figure S2).
In vascular ECs, TNF promotes EC activation/dysfunction but
low levels of apoptosis, notably by inducing protective signaling
pathways. To test the relevance of Notch2 induction and its pro-
apoptotic function in ECs, we test its regulation in a TNF-related
apoptosis model. First, we showed in Figure 3A that EC apoptosis
can be triggered by using the combination of TNF and the
antioxidant pyrrolidine dithiocarbamate (PDTC), also commonly
used as a non specific NFkB inhibitor. Interestingly, as TNF fail to
induce EC apoptosis and correlates with a transient Notch2
activation after 6 h of treatment, the apoptotic combination of
TNF and PDTC was associated with a stronger and sustained
activation of Notch2 receptor between 2 h and 24 h of treatment
(Figure 3B) thus confirming the implication of Notch2 signaling in
EC apoptosis process.
Altogether, these results suggest that a major consequence of
Notch2 activation in vascular ECs is the induction of apoptosis in a
time- and dose-dependent manner.
Activated Notch2 Broadly Represses the Transcription of
Apoptosis Mediators
To examine the underlying mechanisms by which Notch2
NICD sensitizes ECs to apoptosis, an apoptosis-dedicated qRT-
PCR array displaying 88 pro- and anti-apoptotic molecules was
used. Fold changes in gene expression between AdN2ICD- and
AdGFP-transduced ECs are depicted in the Figure 4A, as well as
TNF-treated versus non-treated ECs as control. For the selection of
candidate genes, only transcript exhibiting an over 10-fold ratio
regulation compared to the AdGFP control were considered.
Consequently, 7 candidates were selected; all were down regulated
in response to N2ICD. We found that 5 out of 7 regulated genes
were the pro-apoptotic molecules Bim, death-associated protein
kinase 2 DAPK2, HRK (Harakiri) and DR5 (a TRAIL receptor)
and CD40 whose expression was highly repressed in response to
N2ICD (13.5-, 24.8-, 10.9-, 14.1-, 28.2-fold decrease versus AdGFP
control, respectively; *p,0.05) (Figure 4A). Our findings also
indicate that N2ICD significantly decreases gene transcript levels
for 2 protective molecules: survivin and April (11.9- and 10.7-fold
decreased as compared to control, respectively; *p,0.05).
Decreased transcript levels were further confirmed by qRT-PCR
and found correlated to Notch2 expression (Figure 4B).
Since we found that constitutive expression of N2ICD in
cultured ECs elicits apoptosis but also impairs EC proliferation
(supplemental Figure S3), we speculate that survivin, a potent
regulator of both functions, notably in ECs, also found inhibited
by TNF, could be a key player of Notch2 signaling [20,21].
Therefore, we further examined the possible involvement of
survivin in Notch2-mediated apoptosis. First, Figure 4C confirms
that N2ICD drastically repressed survivin transcript level with a
dose-dependent effect (9.661.0- and 30.861.3-fold decrease at
moi 20 and moi 40, respectively; *p,0.05). Moreover, regulation
of survivin protein expression by Notch2 was confirmed by
western blotting and was found dependent on N2ICD in ECs. Our
results suggest therefore that Notch2 activation could mediate EC
apoptosis by negatively regulating the key protective survivin gene
(Figure 4D).
Notch2 Silencing by RNA Interference Promotes Survivin
Expression and Rescues ECs from Apoptosis
Based on the above results, we further investigated the possible
crosstalk between apoptotic pathway and Notch2 signaling in ECs.
Because many genetic studies showed that the Notch pathway is
very dose-sensitive, we used a loss-of-function model for Notch2
using Notch2 siRNA. This approach was designed to determine
the function of endogenous Notch2 signaling on EC survival. To
test whether inhibition of basal Notch2 could modulate apoptosis,
ECs were transfected with specific Notch2 targeted siRNAs. Non
targeting scramble siRNAs were used as controls. Among the 3
tested siRNAs, 2 displayed a significant down-regulation of
Notch2, at mRNA level by qRT-PCR (71.263.4% 78.666.1%
of inhibition for siN2#1 and #2, respectively, as compared to
control siRNA) (Figure 5A). Figure 5B demonstrates that, in
Notch2 in Endothelial Survival
PLoS ONE | www.plosone.org 5 December 2009 | Volume 4 | Issue 12 | e8244Figure 2. Notch2 activation elicits EC apoptosis.( A) Quantification of EC viability 0–72 h post-infection with AdGFP, AdNull or AdN2ICD using a
DNA content assay. (B) Apoptosis detection 72 h post-transduction after AnnexinV and Propidium Iodide (PI) staining. (C) PhiPhiLux
TM system to
detect real-time activation of caspase3/7 in live ECs after 48 h post-infection for 18 hours, A representative image after imaging is shown in panel C.
Caspase3/7 positive cells/field (in %) were counted every 2 hours during the experiment (D). A western blot analysis for cleaved-forms of caspase-3, -
7 and PARP in response to Notch2 NICD (E). (F) A colorimetric assay for caspase 3 and 7 activation 48 h after transduction.
doi:10.1371/journal.pone.0008244.g002
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silencing significantly increases survivin mRNA in vascular ECs
(9.8- and 7.7-fold increase versus scramble control). This regulatory
effect was further confirmed at protein level by western blotting
(Figure 5C).
To test whether Notch2 inhibition could protect from apoptosis,
ECs were cultured for 48 h after siRNA transfection before
induction of apoptosis by TNF and PDTC treatment (supplemen-
tal Figure S4). Cell death was then quantified by DNA content
analysis (Figure 5D). First, we observed that knockdown of Notch2
did not modify basal EC viability. Moreover, when EC apoptosis is
induced by a 24 h treatment with TNF and PDTC, Notch2
knockdown significantly rescued ECs from apoptosis as compared
to scramble control.
Altogether, these findings suggest that survivin regulation is
controlled at the Notch level and that Notch2 inhibition protects
ECs from apoptosis by increasing survivin expression level.
Notch2-Mediated Endothelial Apoptosis Is Dependent on
Survivin Down-Regulation
To validate the direct implication of survivin in Notch2-
mediated apoptotic functions, we transfected ECs with survivin,
XIAP (a close member of the survivin IAP family) or Bcl2 cDNA
before N2ICD overexpression. Considering a transfection effi-
ciency of 40% in HUVEC with plasmids, ectopic expression of
survivin very efficiently prevents cell apoptosis mediated by
N2ICD (29.564.1% versus 47.366.5% of cell death for Null
control). In contrast, no protective effect was observed with XIAP
nor Bcl2, attesting the specific involvement of survivin in Notch2-
mediated apoptosis in ECs (Figure 6A–B). Because survivin may
directly bind and inhibit caspases, we tested by western blotting
whether survivin decrease in response to Notch2 activation was
implicated in N2ICD-dependent caspase activation. As shown in
Figure 6C, ectopic expression of survivin in N2ICD overexpress-
ing ECs was sufficient to significantly reduce N2ICD-mediated
caspase 7 activation. These results therefore suggest that N2ICD
triggers caspase-dependent apoptosis by decreasing survivin anti-
caspase activity.
Discussion
Here, we provide evidence for a novel link between Notch and
TNF signaling, where Notch2 is activated in response to TNF and
directly controls expression of several genes involved in EC
survival and apoptosis. Activation of Notch2 leads to a rapid
decrease in survivin mRNA and protein expression, and survivin
upregulation was obtained by the selective knockdown of Notch2
in ECs, indicating that survivin regulation is controlled at the
Notch level.
Overall, our study reports a pro-apoptotic role for Notch2
signaling and indicates that specific Notch receptors control distinct
cell fate decisions in the vascular system. The major vascular defects
observed in Notch1
2/2, exacerbated in Notch1
2/2 Notch4
2/2
mutant animals and the restricted expression of Notch4 in ECs led
studies to focus on these Notch receptors in ECs. Notch1 and
Notch4 seems to share common major functions in angiogenesis as
both protect ECs from apoptosis and decrease growth rate
[9,22,23,24,25,26]. These findings also illustrate possible compen-
satory mechanisms in Notch4
2/2 mice by Notch1 which do not
develop severe vascular defects.
Nonetheless, little is known about Notch2 implication in
vascular homeostasis. We show here that Notch2 exerts opposite
effects on EC survival as compared to Notch1 and Notch4. This
pro-apoptotic function has already been reported in breast and
skin cancers [27,28]. However, controversial results in various
cancer models seem to point out cell-type or cellular context
specific orientation of Notch2 apoptotic function [29,30,31,32].
Our findings further substantiated the emerging concept that
the Notch molecules display unique functions. This functional
specificity was already exemplified in the lymphopoietic system by
Figure 3. TNF and PDTC treatment induces EC mortality. EC death induction by DNA content assay (A) and activated cleaved-Notch2
expression by Western Blot (B) after TNF and PDTC treatment. Results are representative of 3 independent experiments. *p,0.05 versus controls.
doi:10.1371/journal.pone.0008244.g003
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PLoS ONE | www.plosone.org 7 December 2009 | Volume 4 | Issue 12 | e8244Figure 4. Notch2 signaling downregulates apoptosis mediators.( A) A schematic representation of apoptosis-related transcripts repressed
(red) or induced (green) by N2ICD or TNF determined by a dedicated PCR array. Means are shown as fold changes compared to AdGFP or untreated
ECs, respectively. (B) Validation of transcripts regulation by qRT-PCR in ECs transduced with AdN2NICD (moi 20 and 40) in comparison to controls
(non infected (NI) and AdGFP) (B–C). (D) Dose-response effect of AdN2ICD on Survivin protein expression by western blot. Results are representative
of 5 independent experiments. *p,0.05 versus controls.
doi:10.1371/journal.pone.0008244.g004
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impaired T-cell development [33], while Notch2 deficiency causes
a dramatic absence of MZB cells [34]. Accordingly, a recent study
demonstrates that activation of different Notch receptors in the
human mammary adenocarcinoma cell line MDA-MB-231 drives
dramatically opposing effects, leading to either increased apoptosis
in the case of Notch2 or increased proliferation in the case of
Notch4 [35]. This is also in line with the finding that different
Notch ICDs have different target sequence selectivity [36]
Strikingly, it remains a critical question how various mamma-
lian Notch receptors and ligands exert their unique functional
activities. Indeed, such specificity is not completely explained by
differential expression patterns or preferential molecular interac-
tions of Notch receptors or ligands, suggesting that other genes can
contribute to specifying Notch receptor functions. Our previous
study [13] and results presented here indicate that TNF elicits a
drastic change in the pattern of Notch receptors expressed on
vascular ECs. This change corresponds to phenotypic switch
where Notch4 is replaced by Notch2. No significant change in
Notch1 protein was observed. Among Notch ligands, only Dll1
was found to be upregulated by inflammatory cytokines (data not
shown), providing a potential mechanism for Notch2 activation in
response to TNF. Functionally, activation of Notch2 signaling
favors cell death while Notch4 activation was shown to be
protective [9]. Thus it is tempting to speculate that cytokines (i.e.
TNF) by modulating Notch signaling and function provide
another step to Notch regulation. Another (non exclusive)
possibility to consider comes from the recent study by Wu et al.
that discovered an unexpected role for the Notch coactivator
Maml1 in mediating the specific signaling of Notch2 [37]. These
findings suggesting that individual Maml coactivators may regulate
molecular specificity of Notch receptor functions remains to be
confirmed.
Apoptosis is believed to be an important factor in vascular
remodeling in normal and pathologic conditions [19]. Survivin is
an inhibitor of apoptosis protein (IAP) that is upregulated in
cancer and has recently been implicated in vascular injury [38].
Survivin was originally detected in tumors; however, subsequent
studies have revealed that many normal adult tissues express
survivin albeit at levels lower than cancer cells. Survivin is an
essential protein in that disruption of the survivin locus in mice
results in early embryonic lethality [39]. This reflects a critical dual
function of survivin in the regulation of cell division and the
preservation of cell viability. The demonstration that survivin
levels in normal tissues can be up-regulated by cytokines suggests
that survivin may have physiologic roles in regulating proliferation
and survival [40]. Although the existence of functional survivin–
caspase complexes is controversial, the ability of survivin to inhibit
apoptosis has been clearly demonstrated [41]. Expression of
survivin protects normal or transformed cells from apoptosis [42]
while forced expression of survivin inhibits various forms of cell
death both in vitro and in vivo [39]. Lack of endothelial cell survivin
resulted in embryonic lethality. Mutant embryos had prominent
and diffuse haemorrhages from embryonic day 9.5 (E9.5) and died
before E13.5 [43], pointing out a key protective role of survivin in
ECs. Our findings are complementary to studies in primary
cultured human ECs and VSMCs where induction of apoptosis by
TNF and cycloheximide or inflammatory cytokines (IFNc, TNF,
IL1b) was completely prevented by survivin overexpression
[21,44]. Moreover, whether survivin inhibition by Notch2 could
be implicated in proliferation blockade resulting from Notch2
induction remains to be verified. Nonetheless, survivin may act
upstream of gene expression and directly influence the transcrip-
tion of pivotal growth-related gene(s) in vascular cells. In the
Figure 5. Notch2 knockdown increases survivin and rescues
ECs from apoptosis.( A) Validation of Notch2 silencing in ECs by qRT-
PCR. (B) qRT-PCR for survivin mRNA in ECs transfected with a scramble
siRNA or siRNAs targeting Notch2. (C) Survivin and Notch2 expression
by western blot. (D) DNA content analysis of siRNA transfected ECs after
induction of apoptosis by TNF and PDTC (NT: non transfected cells).
Results are means6SEM of 3 independent experiments.*p,0.05 versus
scramble.
doi:10.1371/journal.pone.0008244.g005
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cancer and vascular diseases where Notch/survivin signaling plays
a pathogenic role.
In conclusion, we show for the first time that TNF signaling
strongly upregulates and activates Notch2 in vascular ECs. Our
findings further indicate that dysregulated Notch2 signaling
sensitizes vascular ECs to apoptosis and demonstrate a major role
for survivin as effector of Notch signaling.
Supporting Information
Figure S1 Activation of Notch2 signaling in ECs.(A) Dose-
dependent transduction of ECs according to moi for the
recombinant AdGFP and AdN2NICD. Results are expressed as
percentage of GFP-expressing cells determined by flow cytometry
24h post-infection. (B) GFP expression analysis by fluorescence
microscopy in ECs transduced with AdGFP or AdN2ICD. (C)
Western blot for Notch2 and GAPDH expression. Non-infected
(NI) and ECs infected with AdGFP are used as controls. (D)
Immunoreactivity for N2ICD correlated to GFP expression in
nuclei of ECs transduced with AdN2ICD. (E) Cotransfection of
ECs with a CBF1/luciferase reporter plasmid and a plasmid
encoding N2ICD. Controls included non transfected ECs (NT),
CBF1/luc-transfected cells treated with medium or DAPT.
Results are means of 4 independent experiments (arbitrary units).
Found at: doi:10.1371/journal.pone.0008244.s001 (3.78 MB TIF)
Figure S2 AdN2ICD-mediated apoptosis protection by caspase
inhibition. Non infected (NI), AdGFP and AdN2ICD-transduced
HAECs were cultured with or without the pan caspase inhibitor
zvad for 48h. Cell death was measured by DNA content assay.
Results are representative of 3 independent experiments.
Found at: doi:10.1371/journal.pone.0008244.s002 (1.39 MB TIF)
Figure S3 Notch2 inhibits EC proliferation in response to FGF.
Transduced ECs by AdN2ICD (moi 20 and 40) or AdGFP control
vector (moi 5) proliferation in response to FGF was tested by
tritiated-thymidine uptake. Results are means 6 SEM from 3
independent experiments. *p,0.05 vs AdGFP control.
Figure 6. Survivin prevents Notch2-mediated apoptosis. ECs were transduced or not (NT) with AdGFP (5 moi) or AdN2ICD (30 moi) after
transfection with a plasmid encoding survivin, XIAP or Bcl2 full cDNAs or the empty vector (mock) as a control. Cell death was measured by DNA
content (A). Corresponding means6SEM of 7 independent experiments (B). *p,0.05 versus mock. A representative western blotting analysis for
Notch2, survivin and cleaved-caspase 7 expression in ECs non infected (NI) or transduced with AdN2ICD (30 moi) 24 h prior to transfection with mock
or survivin plasmids. Cell lysates were collected 48 h after infection (representative of 3 independent experiments).
doi:10.1371/journal.pone.0008244.g006
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Figure S4 Induction of EC apoptosis by TNF and PDTC
treatment. ECs were treated with TNF and PDTC for 24 h (NT:
non treated cells). Apoptosis was quantified by flow cytometry after
Annexin V and Propidium Iodide (PI) labeling. A representative
dot plot (A) and graphic representation (B) are shown. Results are
means 6 SEM from 3 independent experiments. *p,0.05 vs
untreated cells.
Found at: doi:10.1371/journal.pone.0008244.s004 (1.01 MB TIF)
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